MEMBER SPOTLIGHT
May 2024

Medicus Pharma
**Introduction**

Medicus Pharma Ltd. (TSX.V: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. A wholly owned subsidiary of Medicus Pharma Ltd., SkinJect Inc., is a development stage biotechnology life sciences company focused on commercializing novel treatment for non-melanoma skin cancer, especially basal cell carcinoma, using patented dissolvable doxorubicin-containing microneedle arrays (D-MNA). D-MNA delivers the chemotherapeutic agent transdermally at the site of the lesion to eradicate tumor cells. The relevant U.S. Patent was granted to the University of Pittsburgh and Carnegie Mellon University in 2018. The patents were granted in 2018 and are valid through 2040.

**About Medicus**

Medicus aims to provide an alternative to Mohs surgery, an invasive and painful procedure, by providing an efficacious, non-invasive and painless treatment that is easy to administer in an office setting. The relevant U.S. patent was granted to the University of Pittsburgh and Carnegie Mellon University in 2018. SkinJect secured exclusive worldwide development and commercial rights from the University of Pittsburgh and Carnegie Mellon University in April 2016.

**Medicus seeks to:**
- Demonstrate that doxorubicin-containing microneedle arrays (D-MNA) can penetrate human skin to deliver the chemotherapeutic agent to the site of the lesion, and subsequently dissolve.
- Provide evidence that D-MNA delivered to basal cell carcinoma (BCC) can activate the calreticulin pathway, producing an immune response and apoptosis of cancer cells.

SkinJect completed an FDA approved Phase 1 study in March 2021 for participants with superficial or nodular BCC.
- Phase 1 safety results suggest that D-MNA is safe and well tolerated across different dose levels and subject demographics. All 13 subjects achieved the primary objective of safety and tolerability of the investigational product.
- Efficacy results point to the ability of D-MNA to offer patients a minimally invasive, maximally efficacious treatment option and a better quality of life. Six subjects demonstrated a complete response (CR) with no residual BCC.
- Subjects demonstrating clinical response (CR) presented with nodular type BCC (incidence 60%-70%). Additionally, treatment responses were consistent across dose levels.
A Phase 2 IND clinical Protocol was submitted to the FDA in January 2024 for a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) that is expected to randomize up to 60 patients. The study is designed to evaluate the efficacy of two dose levels (100 and 200 ug) of D-MNA compared to placebo (P-MNA) in subjects with nodular BCC. Patient recruitment is expected to commence in Q2 2024.

**Basal Cell Carcinoma (BCC)**

BCC is the most common cancer in humans, with over 5 million cases diagnosed in the U.S. each year and over 10 million worldwide. BCC is a slow-growing skin tumor, which is commonly seen in dermatology. BCCs rarely metastasize but are frequently multiple and recurrent on sun-exposed skin, with some morbidity.

Surgery is the standard treatment for most BCC patients, either standard excision or Mohs micrographic surgery. The number of BCC procedures is projected to grow at 4% per annum reaching 9.5 million in 2030, representing a market size in excess of $20 billion annually. While most prevalent among the elderly, BCC is becoming more common among younger individuals.

**Microneedles**

Micron-sized (<1000μm in length) microneedles are a rapidly developing method for the transdermal delivery of therapeutic compounds. They function by penetrating the stratum corneum layer of the skin to produce a temporary microchannel through which therapeutic agents may be delivered. Drugs delivered via the transdermal route can bypass some of the issues related to oral and systemic delivery, including large swings in pH, extensive enzymatic activity, liver metabolism, and toxic side effects.

Efficacy rates tied to surgery are high, but there is a substantial unmet need for a non-surgical option that offers strong efficacy and is also cost and time efficient. SkinJect’s aim is to fulfill this unmet need and potentially create a market opportunity in excess of $2 billion annually.

### Leadership

**Raza Bokhari, MD**

Executive Chairman & CEO

A recipient of Philadelphia Business Journal’s “40 under 40” award, Dr. Raza Bokhari – a physician turned serial entrepreneur - has a demonstrated successful track record in aggregating and accelerating life sciences, healthcare services and Pharmaceutical R&D companies.

Dr. Bokhari is the managing partner of RBx Capital, LP and also serves as the Chairman of the Board of Parkway Clinical Laboratories (PCL) a fifty-year-old College of American Pathologist (CAP) accredited, CLIA certified in-vitro diagnostic laboratory.

He previously served as Executive Chairman and CEO of FSD Pharma (Nasdaq: HUGE), where his strategies successfully pivoted the company out of medicinal cannabis and into a clinical stage pharmaceutical R&D, a transition marked by a NASDAQ listing in January 2020, and raising nearly $100M institutional capital to fuel growth and expansion.

Dr. Bokhari has a Doctor of Medicine degree from the University of Punjab, Rawalpindi Medical College, and an Executive MBA from Temple University, Fox School of Business & Management.

In addition to his corporate roles, Dr. Bokhari serves as the Vice Chairman of the World Affairs Council of Philadelphia. He formerly served on the Board of Temple University's Fox School of Business and Management as Chairman of the Executive Advisory Committee and was a Trustee of the esteemed Franklin Institute and Foreign Policy Research Institute.

Dr. Bokhari, through his family foundation, believes in giving back and investing in the community. In recognition of a $1 million gift, he made to his alma mater, Temple University, its Fox Business School named the Innovation & Entrepreneurship Institute Suite in his honor. The school acknowledged Dr. Bokhari in 2018 by naming him a Centennial Honoree, a special collection of entrepreneurs, visionaries, and disruptors who helped shape the Fox School and the business world since 1918. More information on Dr. Bokhari, is available at [www.Razabokhari.com](http://www.Razabokhari.com)
Edward Brennan, MD, FACS is a veteran pharmaceutical and clinical research executive with over 25 years of drug development experience. He has held senior medical leadership roles at major companies, including Wyeth, GlaxoSmithKline, and IndiPharm. As Medical Director at Wyeth and GSK, Dr. Brennan led clinical development programs that resulted in 10 FDA drug approvals. He oversaw teams responsible for all phases of clinical research as well as interactions with regulatory authorities. His therapeutic expertise includes Immunology, Oncology, Women's Health, and Genetic Diseases. Before industry roles, Dr. Brennan practiced medicine as an internist. He received his M.D. from Temple University School of Medicine after completing a Bachelor of Science in Pharmacy.

Edward J. Brennan, MD, FACS
Chief Medical Officer

Ms. Monaco is an accomplished C-suite professional with a successful track record as a leader in the pharmaceutical industry.

Erica brings deep experience in building rapid-growth organizations in the United States, designing, and implementing innovative strategies to build corporate value, obtaining capital financing, and strengthening business performance. Erica joins Medicus with almost 20 years of strategy, investment, and operational experience with demonstrated success within non-profit, for-profit and consultancy arenas.

She has spent the last decade in the dermatology sector with an extensive track record of building start-up operations, accelerating change, and driving process improvement. Mostly recently, Erica was the CEO of Biofrontera Inc. (NSDQ: BFRI). In her role as the CEO of Biofrontera, where she joined as “employee #2”, Erica grew a pre-commercial organization from FDA approval through market introduction and commercial launch, posting a revenue growth at a CAGR over 80% and completing an accretive M&A transaction. Under her watch Biofrontera completed a successful Initial Public Offering (IPO) listing on NASDAQ in 2021 and follow on equity investment rounds in excess of $60M.

Ms. Monaco holds a Master of Accounting degree from the Isenberg School of Management at the University of Massachusetts, Amherst and holds an active CPA license.

Erica Monaco
Chief Operating Officer

Viktoriia Slepeniuk is a multi-talented professional, with a depth of experience in investor relations, trading on Wall Street and strategic sales and marketing in healthcare services.

Before taking the position of Director of Investor Relations at Medicus Pharma, Ltd, Viktoria was the Vice President, Strategic Initiatives, at Parkway Clinical Laboratories, (PCL), a College of American Pathologist (CAP), accredited diagnostic company, serving healthcare providers across United States.

Beginning September 2019, until May 2021, Viktoria was the Manager of Corporate Affairs and Investor Relations at FSD Pharma Inc. (Nasdaq:HUGE).

Viktoria received her Bachelor’s of Arts in International Relations from Chernivtsi National University (Summa Cum Laude) in Ukraine. She enjoys learning about health and wellness in her free time.

Viktoria Slepeniuk
VP, Investor Relations
E: vslepeniuk@medicuspharma.com
T: 609-705-7002